Targeted therapies in gynecologic cancers

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• High-throughput techniques have accelerated the identification of novel molecular targets in human cancer.
• Targeted cancer therapies offer a new generation of drugs interfering with specific molecules critical for tumor growth and progression.
• The success of imatinib mesylate has spurred the development of molecular targeted cancer therapy.

Purpose of the Study:

• To review potential novel molecular targets in gynecologic cancer.
• To discuss the development of targeted therapy for gynecologic cancers.
• To examine the clinical applications of targeted therapy in gynecologic cancers.

Main Methods:

• Review of preclinical and clinical investigations of targeted agents.
• Analysis of drugs targeting tyrosine kinases (EGFR, Her-2/Neu), mTOR, Raf kinase, proteasome, and histone deacetylases.
• Evaluation of agents affecting apoptosis and mitosis.

Main Results:

• Several promising targeted drugs are under development for gynecologic cancers.
• Targeted therapies are significantly changing the treatment landscape for gynecologic cancers.
• Some clinical trials, such as p53 gene therapies, have shown limited success.

Conclusions:

• Targeted therapy represents a significant advancement in gynecologic cancer treatment.
• Continued research into novel molecular targets is crucial for improving patient outcomes.
• Understanding molecular pathways is key to developing effective targeted cancer therapies.